Abstract
Immunotherapy has improved outcomes in non-small cell lung cancer (NSCLC), yet primary and acquired resistance remain common. Pinpointing regulators of tum
Funding Information
  • National Natural Science Foundation of China (No. 82203608)
  • National Natural Science Foundation of China (No. 32300753)
  • Huadong Medicine Joint Funds of the Zhejiang Provincial Natural Science Foundation of China (LHDMY23H160002)
  • Natural Science Foundation of Zhejiang Province (LQN25H160012)

This publication has 47 references indexed in Scilit: